INNATE PHARMA SA (IPH.PA) Stock Income Statement
Europe - Euronext Paris - EPA:IPH - FR0010331421 - Common Stock
1.616 EUR
+0.01 (+0.87%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.00M | 12.62M | 51.90M | 49.58M | 12.11M | |||
| Cost Of Goods | 3.03M | 3.06M | 2.86M | 3.58M | 3.06M | |||
| Gross Profit | 2.97M | 9.57M | 49.05M | 46.00M | 9.05M | |||
| Operating Expenses | 53.97M | 60.94M | 62.14M | 62.42M | 56.87M | |||
| Research and Development | 40.11M | 48.08M | 49.44M | 45.46M | 41.21M | |||
| Selling, General, and Administrative Expenses | 18.59M | 18.00M | 17.00M | 20.24M | 23.35M | |||
| Operating Income | -50.00M | -52.00M | -13.00M | -16.43M | -47.83M | |||
| Interest Income/Expense | 3.66M | 121.00K | 3.45M | 1.09M | 1.26M | |||
| Other Income/Expense | 970.00K | 1.98M | 1.65M | -1.63M | 1.08M | |||
| Non Recurring Items | N/A | 0.00 | 0.00 | -41.00M | N/A | |||
| Income Before Taxes | -46.00M | -49.00M | -7.57M | -57.97M | -45.48M | |||
| Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Net Income | -46.00M | -49.00M | -7.57M | -58.10M | -52.81M | |||
| EBITDA | -48.44M | -50.01M | -7.91M | 28.98M | -43.23M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.55 | -0.61 | -0.09 | -0.73 | -0.66 | |||
| Statistics | ||||||||
| Gross Profit Margin | 49.52% | 75.79% | 94.50% | 92.78% | 74.69% | |||
| Profit Margin | -766.67% | -388.21% | -14.59% | -117.19% | -436.01% | |||
| Operating Profit Margin | -833.33% | -411.98% | -25.05% | -33.13% | -394.86% | |||
All data in EUR